JP5713672B2 - 結核のワクチンおよびその使用方法 - Google Patents

結核のワクチンおよびその使用方法 Download PDF

Info

Publication number
JP5713672B2
JP5713672B2 JP2010503240A JP2010503240A JP5713672B2 JP 5713672 B2 JP5713672 B2 JP 5713672B2 JP 2010503240 A JP2010503240 A JP 2010503240A JP 2010503240 A JP2010503240 A JP 2010503240A JP 5713672 B2 JP5713672 B2 JP 5713672B2
Authority
JP
Japan
Prior art keywords
mycobacterium
tuberculosis
pharmaceutical composition
cells
inactivated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010503240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523711A (ja
JP2010523711A5 (enExample
Inventor
ジェニファー ライター，
ジェニファー ライター，
ジェイソン フィッシャー，
ジェイソン フィッシャー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2010523711A publication Critical patent/JP2010523711A/ja
Publication of JP2010523711A5 publication Critical patent/JP2010523711A5/ja
Application granted granted Critical
Publication of JP5713672B2 publication Critical patent/JP5713672B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010503240A 2007-04-12 2008-04-11 結核のワクチンおよびその使用方法 Expired - Fee Related JP5713672B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92330107P 2007-04-12 2007-04-12
US60/923,301 2007-04-12
PCT/US2008/060065 WO2008128065A2 (en) 2007-04-12 2008-04-11 Tuberculosis vaccine and method of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014212560A Division JP2015038130A (ja) 2007-04-12 2014-10-17 結核のワクチンおよびその使用方法

Publications (3)

Publication Number Publication Date
JP2010523711A JP2010523711A (ja) 2010-07-15
JP2010523711A5 JP2010523711A5 (enExample) 2011-04-07
JP5713672B2 true JP5713672B2 (ja) 2015-05-07

Family

ID=39523390

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010503240A Expired - Fee Related JP5713672B2 (ja) 2007-04-12 2008-04-11 結核のワクチンおよびその使用方法
JP2014212560A Pending JP2015038130A (ja) 2007-04-12 2014-10-17 結核のワクチンおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014212560A Pending JP2015038130A (ja) 2007-04-12 2014-10-17 結核のワクチンおよびその使用方法

Country Status (14)

Country Link
US (3) US8394389B2 (enExample)
EP (1) EP2144626B8 (enExample)
JP (2) JP5713672B2 (enExample)
AU (1) AU2008240181B2 (enExample)
CA (1) CA2682870C (enExample)
CY (1) CY1117290T1 (enExample)
DK (1) DK2144626T3 (enExample)
ES (1) ES2531018T3 (enExample)
HR (1) HRP20150177T1 (enExample)
HU (1) HUE024427T2 (enExample)
PL (1) PL2144626T3 (enExample)
PT (1) PT2144626E (enExample)
SI (1) SI2144626T1 (enExample)
WO (1) WO2008128065A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2144626T3 (en) 2007-04-12 2015-02-09 Mico Bio Inc Tuberculosis vaccine and method of using same
KR101814857B1 (ko) 2011-04-06 2018-01-04 바이오백심 리미티드 인간에서의 hiv 질환의 예방 및/또는 치료를 위한 제약 조성물
WO2012137072A1 (en) 2011-04-06 2012-10-11 Biovaxim Limited Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans
CA2833633A1 (en) * 2011-04-20 2012-10-26 Jason Fisher Composition and method for enhancing an immune response
ES2438690B1 (es) * 2012-06-15 2015-01-16 Fundació Institut Per A La Investigació En Ciències De La Salut "Germans Trias I Pujol" (Igtp) Unitat De Tuberculosi Experimental Micobacterias inactivadas para su uso por vía oral en la prevención de la tuberculosis
WO2014001571A1 (en) * 2012-06-29 2014-01-03 Lysando Ag Composition for use in mycobacteria diagnosis
EP2679232A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria vaccination
EP2679677A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
KR101615186B1 (ko) 2014-03-07 2016-04-25 연세대학교 산학협력단 결핵 백신의 면역효과 증강용 조성물 및 면역효과 증진 방법
KR101631054B1 (ko) * 2015-12-31 2016-06-16 중앙대학교 산학협력단 마이코박테리아 유래 CFP-10 또는 Ag85B에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
US10279031B2 (en) * 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
CN108743931B (zh) * 2018-05-02 2022-08-16 成都威斯克生物医药有限公司 抗结核病疫苗及其制备方法和用途
ES2962407T3 (es) 2018-12-04 2024-03-18 Sabiotec Spin Off S L Inmunoestimulante para su uso contra patógenos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4724114A (en) 1984-04-23 1988-02-09 Kimberly-Clark Corporation Selective layering of superabsorbents in meltblown substrates
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
EP1467771B1 (en) 2001-11-14 2008-04-16 Novavax, Inc. Mycobacterial vaccine
WO2003075824A2 (en) 2002-03-08 2003-09-18 Modi, Rajiv, Indravadan Process of manufacturing pharmaceutical composition useful for management of tuberculosis
JP5219808B2 (ja) * 2005-06-23 2013-06-26 ステイテンス・セラム・インスティテュート 改良された結核ワクチン
DK2144626T3 (en) 2007-04-12 2015-02-09 Mico Bio Inc Tuberculosis vaccine and method of using same

Also Published As

Publication number Publication date
AU2008240181B2 (en) 2014-01-09
JP2010523711A (ja) 2010-07-15
DK2144626T3 (en) 2015-02-09
SI2144626T1 (sl) 2015-04-30
WO2008128065A3 (en) 2008-12-18
PL2144626T3 (pl) 2015-09-30
CY1117290T1 (el) 2017-04-26
US8394389B2 (en) 2013-03-12
CA2682870C (en) 2016-08-09
EP2144626B8 (en) 2015-02-18
US20150258187A1 (en) 2015-09-17
HRP20150177T1 (hr) 2015-04-10
EP2144626A2 (en) 2010-01-20
ES2531018T3 (es) 2015-03-09
US9636391B2 (en) 2017-05-02
AU2008240181A1 (en) 2008-10-23
US8932608B2 (en) 2015-01-13
HUE024427T2 (en) 2016-01-28
WO2008128065A2 (en) 2008-10-23
US20130273110A1 (en) 2013-10-17
PT2144626E (pt) 2015-03-03
CA2682870A1 (en) 2008-10-23
EP2144626B1 (en) 2014-12-03
JP2015038130A (ja) 2015-02-26
US20100112007A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
JP5713672B2 (ja) 結核のワクチンおよびその使用方法
JP2010523711A5 (enExample)
Jia et al. Nasal and pulmonary vaccine delivery using particulate carriers
JP2014512388A (ja) 免疫反応を増進するための組成物および方法
JP6061859B2 (ja) デンプンを使用する経口ワクチン速溶性剤型
US9585955B2 (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
RU2526910C2 (ru) Профилактическая вакцина от туберкулеза
Giri et al. Is intranasal vaccination a feasible solution for tuberculosis?
Carpenter et al. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu
ES2335177B1 (es) Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
US9585954B2 (en) Mucosal immunization
JP2006515354A (ja) 医薬エアロゾル組成物
EP3134118B1 (en) Particulate vaccine formulations for inducing innate and adaptive immunity
RU2678981C2 (ru) Композиция от бешенства, содержащая адъювант pika
Neustrup Nanoparticles and microfluidics for future tuberculosis accines
AU2014201218A1 (en) Tuberculosis vaccine and method of using same
Sarim Imam et al. Pulmonary Vaccine Delivery Systems: A Novel Approach for Immunization
JP2013510188A (ja) 黄色ブドウ球菌に由来する菌血症関連抗原
JP2018008908A (ja) 人以外の陸上動物用のウイルス感染症に対する抗体誘導剤とその補助剤
OA16638A (en) Composition and method for enhancing an immune response.
HK1118013B (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130115

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130208

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141126

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150310

R150 Certificate of patent or registration of utility model

Ref document number: 5713672

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees